{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T11:12:47Z","timestamp":1648897967494},"reference-count":25,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The virological response after an 8-day maraviroc monotherapy has been proposed to be an alternative method to determine whether an CCR5 antagonist should be prescribed to HIV-infected patients. The frequency of patients eligible for a combined antiretroviral therapy which includes maraviroc on the basis of the result of this clinical test is not well-known at the moment. In the same way, clinical and immunovirological factors associated with the virological response after antagonist exposure need to be determined. Ninety consecutive HIV-infected patients were exposed to an 8-day maraviroc monotherapy. The virological response was considered positive if either a reduction of \u22651-log\n            <jats:sub>10<\/jats:sub>\n            HIV RNA copies\/ml or an undetectable viral load (&lt;40 HIV RNA copies\/ml) was achieved. CXCR4- and CCR5-tropic virus levels were determined by using patients' viral isolates and multiple rounds of infection of indicator cell lines (U87-CXCR4 and U87-CCR5). The frequency of patients with a positive virological response was 72.2% (94.7% and 66.2% for treatment-na\u00efve and pretreated patients, respectively). The positive response rates dramatically decreased in patients with lower CD4\n            <jats:sup>+<\/jats:sup>\n            T-cell counts. The CXCR4-tropic virus level was the only variable independently associated with the virological response after short-term maraviroc exposure. Lower CD4\n            <jats:sup>+<\/jats:sup>\n            T-cell strata were associated with higher CXCR4-tropic virus levels. These results support the suggestion that CCR5 antagonists should be an early treatment option before the expansion of CXCR4-tropic strains.\n          <\/jats:p>","DOI":"10.1128\/aac.00753-11","type":"journal-article","created":{"date-parts":[[2011,8,2]],"date-time":"2011-08-02T03:15:12Z","timestamp":1312254912000},"page":"4664-4669","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":9,"title":["Virological Response after Short-Term CCR5 Antagonist Exposure in HIV-Infected Patients: Frequency of Subjects with Virological Response and Associated Factors"],"prefix":"10.1128","volume":"55","author":[{"given":"Ezequiel","family":"Ruiz-Mateos","sequence":"first","affiliation":[{"name":"Laboratory of Immunovirology, Biomedicine Institute of Seville (IBIS), Service of Infectious Diseases, Virgen del Roc\u00edo University Hospital, Seville, Spain"},{"name":"Department of Clinical Biochemistry, Biomedicine Institute of Seville (IBIS)\/Virgen del Roc\u00edo University Hospital, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Gonz\u00e1lez-Serna","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirology, Biomedicine Institute of Seville (IBIS), Service of Infectious Diseases, Virgen del Roc\u00edo University Hospital, Seville, Spain"},{"name":"Department of Clinical Biochemistry, Biomedicine Institute of Seville (IBIS)\/Virgen del Roc\u00edo University Hospital, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Genebat","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirology, Biomedicine Institute of Seville (IBIS), Service of Infectious Diseases, Virgen del Roc\u00edo University Hospital, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kawthar","family":"Machmach","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirology, Biomedicine Institute of Seville (IBIS), Service of Infectious Diseases, Virgen del Roc\u00edo University Hospital, Seville, Spain"},{"name":"Department of Clinical Biochemistry, Biomedicine Institute of Seville (IBIS)\/Virgen del Roc\u00edo University Hospital, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc","family":"Vidal","sequence":"additional","affiliation":[{"name":"Hospital Universitari Joan XXIII, IISPV, Universitat Rovira I Virgili, Tarragona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngeles","family":"Mu\u00f1oz-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Laboratorio de Inmuno-Biolog\u00eda Molecular, Gregorio Mara\u00f1\u00f3n University Hospital, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Ferrando-Martinez","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirology, Biomedicine Institute of Seville (IBIS), Service of Infectious Diseases, Virgen del Roc\u00edo University Hospital, Seville, Spain"},{"name":"Laboratorio de Inmuno-Biolog\u00eda Molecular, Gregorio Mara\u00f1\u00f3n University Hospital, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Leal","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirology, Biomedicine Institute of Seville (IBIS), Service of Infectious Diseases, Virgen del Roc\u00edo University Hospital, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/34571"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21425"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/650697"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4721-4732.2005"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181f25bab"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2010.11.015"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp293"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.2174\/157016210793499295"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00953-10"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.5.555"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-9-199305010-00004"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/592052"},{"key":"e_1_3_2_14_2","first-page":"530","article-title":"CXCR4 overexpression during the course of HIV-1 infection correlates with the emergence of X4 strains","volume":"39","author":"Lin Y. L.","year":"2005","unstructured":"LinY. L. . 2005. CXCR4 overexpression during the course of HIV-1 infection correlates with the emergence of X4 strains. J. Acquir. Immune Defic. Syndr. 39:530\u2013536.","journal-title":"J. Acquir. Immune Defic. Syndr"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282ef81ea"},{"key":"e_1_3_2_16_2","volume-title":"Abstr. XVIII Int. AIDS Conf.","author":"Mills A.","year":"2010","unstructured":"MillsA. . 2010. Once-daily maraviroc (MVC) + atazanavir\/ritonavir (ATV\/r) versus emtricitabine\/tenofovir (TDF\/FTC) + ATV\/r in treatment na\u00efve patients: a week 24 planned interim analysis, abstr. THLBB203. Abstr. XVIII Int. AIDS Conf."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1310\/hct1006-394"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp063"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830ebcd4"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.2.802-809.2006"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3280f00f9f"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1310\/hct1103-125"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq030"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/587660"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00853-06"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir072"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00753-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00753-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:55:22Z","timestamp":1645480522000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00753-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1128\/AAC.00753-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.00753-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"2011-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-07-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-09-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}